secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001636282-24-000085
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end
--------------------------------------------------------------------------------

- Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.
- Cash, cash equivalents and marketable securities of $414.2M as of Sep 30, 2024; runway extended well into 2027.
- SPY001 Phase 1 interim data expected by year-end 2024; SPY002 FIH trials initiated in Q4 2024.
- Appointed Sheldon Sloan, M.D., as Chief Medical Officer, effective October 2024.
- Preclinical data for SPY003 at UEGW showed >3-fold half-life extension vs risankizumab; FIH accelerated to Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000085/0001636282-24-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000085/syre-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001636282-24-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer